1. Evaluating Nanomedicines: Obstacles and Advancements
Magdalena Swierczewska, Rachael M. Crist, and Scott E. McNeil
Part II Sterility and Endotoxin Testing
2. Detection of Bacterial Contamination in Nanoparticle Formulations by Agar Plate Test
Timothy M. Potter, Barry W. Neun, Anna N. Ilinskaya, and Marina A. Dobrovolskaia
3. Considerations and Some Practical Solutions to Overcome Nanoparticle Interference with LAL Assays and to Avoid Endotoxin Contamination in Nanoformulations
Barry W. Neun and Marina A. Dobrovolskaia
Part III Physicochemical Characterization
4. Elemental Analysis in Biological Matrices Using ICP-MS
Matthew N. Hansen and Jeffrey D. Clogston
5. PEG Quantitation Using Reversed Phase High Performance Liquid Chromatography and Charged Aerosol Detection
Mackensie C. Smith and Jeffrey D. Clogston
6. Quantitation of Surface Coating on Nanoparticles Using Thermogravimetric Analysis
Alpana A. Dongargaonkar and Jeffrey D. Clogston
7. Immunoelectron Microscopy for Visualization of Nanoparticles
Sarah R. Anderson, David Parmiter, Ulrich Baxa, and Kunio Nagashima
8. Imaging of Liposomes by Transmission Electron Microscopy
Ulrich Baxa
Part IV Immunology
9. Updated Method for In Vitro Analysis of Nanoparticle Hemolytic Properties
Barry W. Neun, Anna N. Ilinskaya, and Marina A. Dobrovolskaia
10. In Vitro Assessment of Nanoparticle Effects on Blood Coagulation
Timothy M. Potter, Jamie C. Rodriguez, Barry W. Neun, Anna N. Ilinskaya, Edward Cedrone, and Marina A. Dobrovolskaia
11. In Vitro Analysis of Nanoparticle Effects on the Zymosan Uptake by Phagocytic Cells
Timothy M. Potter, Sarah L. Skoczen, Jamie C. Rodriguez, Barry W. Neun, Anna N. Ilinskaya, Edward Cedrone, and Marina A. Dobrovolskaia
12. Assessing NLRP3 Inflammasome Activation by Nanoparticles
Bhawna Sharma, Christopher B. McLeland, Timothy M. Potter, Stephan T. Stern, and Pavan P. Adiseshaiah
13. Analysis of Complement Activation by Nanoparticles
Barry W. Neun, Anna A. Ilinskaya, and Marina A. Dobrovolskaia
14. Methods for Analysis of Nanoparticle Immunosuppressive Properties In Vitro and In Vivo
Timothy M. Potter, Barry W. Neun, and Marina A. Dobrovolskaia
15. Analysis of Pro-Inflammatory Cytokine and Type II Interferon Induction by Nanoparticles
Timothy M. Potter, Barry W. Neun, Jamie C. Rodriguez, Anna N. Ilinskaya, and Marina A. Dobrovolskaia
16. Analysis of Nanoparticle Adjuvant Properties In Vivo
Barry W. Neun and Marina A. Dobrovolskaia
17. In Vitro and In Vivo Methods for Analysis of Nanoparticle Potential to Induce Delayed Type Hypersensitivity Reactions
Timothy M. Potter, Barry W. Neun, and Marina A. Dobrovolskaia
18. Autophagy Monitoring Assay II: Imaging Autophagy Induction in LLC-PK1 Cells Using GFP-LC3 Protein Fusion Construct
Pavan P. Adiseshaiah, Sarah L. Skoczen, Jamie C. Rodriguez, Timothy M. Potter, Krishna Kota, and Stephan T. Stern
Part V Drug Release and In Vivo Efficacy
19. Improved Ultrafiltration Method to Measure Drug Release from Nanomedicines Utilizing a Stable Isotope Tracer
Sarah L. Skoczen and Stephan T. Stern
20. Designing an In Vivo Efficacy Study of Nanomedicines for Preclinical Tumor Growth Inhibition
Pavan P. Adiseshaiah and Stephan T. Stern
This second edition volume expands on the first edition by providing up-to-date protocols to characterize nanomaterials used as drug delivery agents. The chapters in this book are divided into 5 parts and cover topics such as: advances and obstacles in nanomedicine research; methods to test sterility and endotoxin, physicochemical features, immunological effects, drug release, and in vivo efficacy. Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls.
Cutting-edge and comprehensive, Characterization of Nanoparticles Intended for Drug Delivery, Second Edition is a valuable tool for researchers and pharmaceutical and biotechnology developers who are evaluating the clinical potential of nanomedicines in preclinical studies.>